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Background: In renal patients estimation of GFR is routinely done by means of population-based formulae using
serum creatinine levels. For GFR determination in the creatinine-blind regions or in cases of reno-hepatic syndrome
as well as in critical cases of live kidney donors individualized measurements of GFR (mGFR) employing the kinetics
of exogenous filtration markers such as the inulin-like polyfructosan sinistrin are necessary. The goal of this study is
to compare mGFR values with the eGFR values gained by the Modification of Diet in Renal Disease (MDRD4) and
Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formulae.
Methods: In 170 subjects comprising persons with normal renal function or with various stages of kidney diseases
(CKD 1-4) GFR was measured by application of intravenous bolus of sinistrin and assessment of temporal plasma
concentration profiles by means of pharmacokinetic methods (mGFR). Comparisons of mGFR with MDRD4- and
CKD-EPI-derived eGFR values were performed by means of linear regression and Bland-Altman analyses.
Results: Reasonable agreement of mGFR and eGFR values was observed in patients with poor renal function [GFR
below 60 (ml/min)/1.73 m2]. In cases of normal or mildly impaired renal function, GFR determination by MDRD4 or
CKD-EPI tends to underestimate GFR. Notably, there is practically no difference between the two eGFR methods.
Conclusions: For routine purposes or for epidemiological studies in cases of poor renal function eGFR methods are
generally reliable. But in creatinine-blind ranges [GFR above 60 (ml/min)/1.73 m2] eGFR values are unreliable and
should be replaced by clinically and physiologically suitable methods for mGFR determination.
Consort: http://www.consort-statement.org/index.aspx?o=1190
Keywords: eGFR, MDRD, CKD-EPI, mGFR, Sinistrin, KineticsBackground
For routine applications or for epidemiological studies,
GFR values are estimated on the basis of individual serum
creatinine measurements by means of regression formulae,
e.g., the MDRD4 and CKD-EPI formulae [1-4]. These so-
called eGFR formulae are derived from population-data
describing the relations between GFR values obtained by a* Correspondence: sabine.zitta@medunigraz.at
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reproduction in any medium, provided the orkinetic methods (mGFR) and the corresponding concen-
trations of serum creatinine [5].
Unfortunately, these formula-derived GFR-values are
problematic in individuals with normal or mildly im-
paired renal function. Several reasons are responsible for
this problem, such as, e.g., the natural variation of the
original population data in combination with the confi-
dence intervals increasing with decreasing creatinine
concentrations, and the increasing impact of analytical
uncertainties of creatinine measurements particularly in
low concentration ranges. In addition, disturbed creatin-
ine production, e.g. in patients with liver diseases, mayd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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creatinine-based eGFR formulae. Rather, formulae-derived
GFR estimations tend to be of use in the presence of mod-
erately or severely impaired renal function, i.e., GFR below
60 (ml/min)/1.73 m2 only [6,7].
For accurate assessment of renal function above this
threshold pharmacokinetics of exogenous markers such as
I125-iothalamate or Cr51-EDTA or inulin should be used [8].
Sinistrin, an inulin-like polyfructosan, is a physiologically and
clinically advantageous GFRmarker, which is only filtered by
the glomeruli and is metabolically inert [9-12]. In contrast to
the original ‘gold standard’ method of constant intravenous
infusion of inulin for determination of glomerular filtration
rate [13], modern techniques use intravenous bolus injec-
tions of test substances and algorithms for fitting of bi-
exponential functions to the temporal concentration profiles
observed. GFR is determined by dividing the dose applied
through the area under the curve estimated with the fitted
function parameters [14]. Attainment of a steady state is
not required, and only raw guesses of the kinetic constants
are required before starting the fitting algorithm.
The aim of the present study is to compare the ranges
of validity and the information content which can be
gained from the commonly used formulae-based estima-
tions of GFR (MDRD4 and CKD-EPI) with a kinetic
technique using sinistrin in a single injection application
as standard for comparison, particularly in CKD 1-2.
Thereby, the paper emphasizes the use of a kinetic method
employing a physiological marker especially suitable for
the renal evaluation of live kidney donors or kidney trans-
plant patients. To our knowledge this paper represents the
first report on the application of this kinetic procedure in
subjects with normal renal function as well as in patients
with chronic kidney disease (CKD 1-4).
Methods
All of the included measurements were performed dur-
ing routine visits within the standard care program ofTable 1 Basic characteristics of the patients investigated
Diagnosis Number Age (y
Potential live kidney donor 12 45.4 (2
Kidney transplant recipient 36 43.9 (2
Malignancy 35 45.3 (2
Kidney stones 9 43.2 (2
Hypertension 32 48.1 (2
Diabetes mellitus 14 44.5 (2
Glomerulonephritis 21 46.2 (2
Unilateral nephrectomy 5 36.0 (2
Recompensated acute renal failure 5 44.2 (2
Unilateral duplexed kidney 1 18.7
Shown are mean values and ranges (in parentheses).the Division of Nephrology and Hemodialysis at the Medical
University of Graz. An ethical approval was obtained from
the ethical committee of the Medical University of Graz to
use the results of these examinations for the presented study.
Subjects
Clearance measurements were performed in 170 sub-
jects (100 females, 70 males), mean age 45 years (range
18.7 – 89.5), mean serum creatinine 1.22 mg/dl (range
0.5 – 6.7), with different underlying diseases: 12 subjects
were screened prior to living kidney donation and 36 pa-
tients after kidney transplantation. 35 patients suffering
from breast cancer were tested prior to chemotherapy, 9
patients with kidney stones prior to lithotripsy, 32 pa-
tients had mild hypertension, 14 suffered from diabetes,
21 had glomerulonephritis, 5 patients had a history of
unilateral nephrectomy, 5 patients were tested after
recompensation of an acute renal failure, and 1 subject
had a unilateral duplex kidney. Each subject gave written
informed consent. Table 1 shows the distributions of
age, body mass and serum creatinine concentration
among these groups of patients.
Clinical procedures and techniques of clinical chemistry
Serum creatinine was determined by the Jaffe method
(Hitachi, Roche Diagnostic GmbH, Mannheim, Germany)
using a kinetic colorimetric assay. The temporal con-
centration profiles of sinistrin (Inutest®; Fresenius-Kabi,
Linz, Austria) after intravenous injection of 2500 mg
during 3 minutes were determined by drawing samples
from venous blood 10, 20, 30, 45, 60, 90, 120, 150, and
180 min after bolus injection of the marker. After cen-
trifugation of the samples the initial concentration of
blood glucose was determined. Thereafter, sinistrin was
hydrolyzed to yield fructose monomers. Fructose was
enzymatically converted to glucose, and the latter was en-
zymatically oxidized using NAD. The resulting NADH
was assessed photometrically by its extinction of UV [15].r) Body mass (kg) Creatinine (mg/dL)
8.4 – 68.4) 74.4 (59 – 86) 1.0 (0.7 – 1.3)
3.7 – 65.2) 70.1 (50 – 88) 1.5 (0.7 – 3.2)
3.5 – 89.5) 70.5 (50 – 93) 1.0 (0.5 – 6.7)
4.4 -62.9) 85.8 (70 – 104) 1.1 (1.0 – 1.2)
3.9 – 69.1) 75.3 (51 – 100) 1.1 (0.6 – 2.5)
9.0 – 65.9) 73.5 (50 – 95) 1.1 (0.8 – 2.5)
2.1 – 74.2) 78.9 (52 – 108) 1.6 (0.5 – 4.1)
1.8 – 45.2) 69.2 (58 – 86) 1.4 (0.8 – 3.1)
3.7 – 63.2) 67.4 (55 – 81) 1.0 (0.8 – 1.3)
58.0 0,8
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tions is used to constitute a measure of the sinistrin con-
centration. All GFR measurements are given standardized
in (ml/min)/1.73 m2. Within-day CVs for sinistrin were
1.4% at a concentration of 75 mg/L and 1.2% at 275 mg/L.
Between-day CVs were 3.3% at 75 mg/mL and 1.6% at 275
mg/L sinistrin.
Model description and biometric methods
Experiments with sinistrin have shown that its elimin-
ation kinetics after a bolus injection can be adequately
described by a two-compartment model as depicted in
Figure 1 [16]. The well-perfused part of the extra-
cellular fluids is considered as the central volume into
which the exogenous marker sinistrin is injected, and
from which it is on the one hand exchanged with the
so-called peripheral compartment comprising the less
perfused part of the interstitium, and on the other
hand eliminated via the kidneys [17]. Mathematically
such a system can be represented by the well-known
two-compartment model of pharmacokinetics con-
taining characteristic system constants, namely, the
relative transfer rates for the substance exchangesFigure 1 The two-compartment model of pharmacokinetics.between the two compartments, the rate constant for
the eliminating flow from the central compartment to
the outside and the volume of the central compart-
ment. From these system constants, or parameters in
a mathematical sense, can be derived other model
parameters such as the clearance (GFR), the peripheral
volume, and a characteristic retention time in the per-
ipheral volume. GFR especially is determined as the
product of the rate constant of the elimination and
the central volume.
The adaptation of the two-compartment model to
the experimentally determined kinetic data profile,
yielding the system constants as well as their res-
pective standard estimation errors due to the noise in
the experimental data, was done by embedding the
analytical solution of the model [18] into a nonlinear
regression procedure [19]. However, it could also be
done by employing a commercially available pharma-
cokinetic software package (SAAM II, Software App-
lication for Kinetic Analyses, Version 2.0, ©University
of Washington) [20].
GFR estimations based on serum creatinine were
performed by means of the MDRD4 – and CKD-EPI
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eGFR was calculated as follows:
eGFR (mL/min) = 186 × SCr -1.154 × age -0.203 (× 0.742
if female) (× 1.21 if black)
The CKD-EPI GFR was calculated gender specifically
and stratified by creatinine levels according to the fol-
lowing equations:
Female with SCr ≤ 0.7 mg/dl
eGFR (ml/min) = 144 × 0.993 age × (SCr / 0.7) -0.329
(× 1.15 if black)
Female with SCr > 0.7 mg/dl
eGFR (ml/min) = 144 × 0.993 age × (SCr / 0.7) -1.209
(× 1.15 if black)
Male with SCr ≤ 0.9 mg/dl
eGFR (ml/min) = 141 × 0.993 age × (SCr / 0.9) -0.411
(× 1.16 if black)
Male with SCr > 0.9 mg/dl
eGFR (ml/min) = 141 × 0.993 age × (SCr / 0.9) -1.209
(× 1.16 if black)
An initial comparison of kinetically measured mGFR
with creatinine-based eGFR values was performed by
linear regression and correlation techniques. It is well
known, however, that these techniques are not well
suited for assessing agreement between different analy-
tical methods, and thus, we also analyzed our data
according to the method by Bland and Altman [22,23]: the
differences between the two methods (bias = mGFR –
eGFR) are plotted against the common mean values. Thus,
the bias of the two methods, together with its 95%Figure 2 Temporal profiles of observed (small circles) and model-ada
bolus of 2500 mg sinistrin in a normal subject.confidence intervals and the so called limits of agreement
can be obtained.
Results
In order to illustrate the method chosen for the meas-
urement of GFR, the result of fitting a pharmacokinetic
two-compartment model to the observed temporal con-
centration profile of sinistrin is given for an individual
with normal renal function (Figure 2).
To illustrate the association between kinetically
determined GFR and creatinine based eGFR, Figure 3
shows the results obtained for the CKD-EPI formula:
the left panel of Figure 3 shows a classical linear
regression analysis, and the right panel visualizes the
outcome of the Bland-Altman technique for the same
data. (The MDRD4 formula would yield a graphical
representation being nearly indistinguishable from Figure 3;
so we do not show it explicitly.) Obviously, while the lin-
ear regression apparently shows reasonably narrow 95%
confidence bounds of the regression line, there is consid-
erable scatter of the measurements and, more importantly,
the slope of the regression line deviates significantly from
the line of identity (which would indicate perfect agree-
ment of the two methods). Rather, the slope indicates
significant underestimation of eGFR values, compared
with the kinetically determined mGFR. In agreement with
these unfavorable conclusions from the linear regression
analysis, also the Bland-Altman analysis shows statistically
highly significant positive bias (the eGFR values are con-
sistently lower than mGFR), and the limits of agreement
between the two methods indicate inacceptable deviations.
Table 2 (column “Total mGFR range”) substantiates
these findings in quantitative manner for both eGFR
methods. As the Bland-Altman plot in Figure 3pted concentration of sinistrin (smooth line) after an intravenous
Figure 3 Analysis of agreement between mGFR and eGFR according to the CKD-EPI formula. Left: Linear regression analysis results: the
thick line represents the regression line; the two medium thick hyperbolic lines show the 95% confidence intervals of the regression line. For
comparison, the thin dashed line along the diagonal represents the line of identity. Right: Results of the Bland-Altman analysis: the solid
horizontal line shows the bias, and the two dashed horizontal lines visualize the limits of agreement between both methods. For all three lines,
also the 95% confidence intervals are indicated. Note that bias is defined as mean of mGFR minus mean of eGFR.
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ically obtained mGFR and either of the eGFR tend to
grow with growing mean value of the measurements:
the bias obviously is smaller for small mean values,
and larger for large mean values. Therefore, Table 2
shows also the results obtained by stratifying the stat-
istical analyses according to mGFR: including into the
analyses only patients with severely disturbed renal
function [mGFR <= 60 (mL/min)/ 1.73 m2], the statis-
tical criteria show much better agreement between
mGFR and both eGFR values; however, patients with
better renal function [mGFR > 60 (mL/min)/ 1.73 m2]
in accordance with the graphical representation ex-
hibit even worse results. Splitting the latter group ofTable 2 Results of the linear regression analyses as well the B
values (dependent variable) versus the kinetically determined
eGFR Variable Total mGFR range mGFR <= 60
(mL/min)/1.73
CKD-EPI Intercept 14.7 (6.9 – 22.4) −9.8 (-29.5 – 9.9
Slope 0.67 (0.59 – 0.75) 1.13 (0.71 – 1.55
R* 0.78 (0.71 – 0.83) 0.66 (0.44 – 0.80
Bias+ 14.8 (11.8 – 17.9) 3.8 (-1.3 – 8.9)
Limits of agreement −24.9 – 54.6 −27.9 – 35.6
MDRD Intercept 14.9 (7.0 – 22.9) −6.7 (-24.4 – 11
Slope 0.64 (0.55 – 0.72) 1.03 (0.66 – 1.41
R 0.76 (0.69 – 0.82) 0.67 (0.46 – 0.81
Bias 17.9 (14.7 – 21.1) 5.2 (0.6 – 9.7)
Limits of agreement −23.5 – 59.3 −23.1 – 33.5
*R, linear correlation coefficient.
+Bias is defined as mean of mGFR minus mean of eGFR.patients again according to a cut-off threshold of
mGFR smaller or larger than 90 (mL/min)/ 1.73 m2
(mildly disturbed versus normal renal function), simi-
lar results are obtained with the worst agreement seen
in individuals with normal mGFR > 90 (mL/min)/
1.73 m2. (Further stratification was not performed
since in the smaller strata the number of individuals
becomes critically low.)
There is no real difference between the MDRD4- and
the CKD-EPI-methods over the GFR ranges studied. As
can be seen from Table 2, the results of the linear regres-
sion as well as the Bland-Altman analyses using either
MDRD or CKD-EPI-eGFR values as dependent variable
are nearly identical, both over the total GFR range andland-Altman-analyses of the creatinine-based eGFR








) 34.7 (20.5 – 48.9) 1.7 (-44.8 – 48.2) 64.9 (41.3 – 88.2)
) 0.49 (0.36 – 0.62) 0.86 (0.25 – 1.47) 0.24 (0.04 – 0.44)
) 0.55 (0.42 – 0.66) 0.47 (0.14 – 0.71) 0.23 (0.03 – 0.41)
18.4 (14.8 – 21.9) 8.6 (3.2 – 14.1) 21.5 (17.3 – 25.7)
−21.4 – 51.9) −20.2 – 37.6 −19.3 – 62.2
.0) 34.7 (19.0 – 49.1) 10.4 (-30.2 – 51.1) 61.3 (35.4 – 87.2)
) 0.46 (0.32 – 0.60) 0.72 (0.18 – 1.25) 0.24 (0.01 – 0.46)
) 0.50 (0.36 – 0.62) 0.45 (0.11 – 0.69) 0.21 (0.01 – 0.3)
22.0 (18.2 – 25.7) 11.1 (6.3 – 15.9) 25.4 (20.9 – 29.9)
−19.9 – 63.9 −14.6 – 36.9 −18.4 – 69.3
Zitta et al. BMC Nephrology 2013, 14:159 Page 6 of 8
http://www.biomedcentral.com/1471-2369/14/159in the various subranges studied. As expected, therefore,
a linear regression analysis between MDRD and CKD-
EPI results yields a nearly perfect agreement with
an intercept of 0.24 (95% c.i., -2.0 – 2.5), a slope of 0.96
(0.93 – 0.98) and a correlation coefficient of 0.98 (0.976 –
0.987). The Bland-Altman analysis of the agreement
between both eGFR measurements yields a bias of 3.1
(2.3 – 3.9) with acceptable limits of agreement (-7.1 –
13.3). Accordingly, there are also no relevant differences
in the overall diagnostic powers of the two eGFR formu-
lae, taking 60 ml/min/1.73 m2 as mGFR cut-off value
gained by the kinetic procedure: for the MDRD-formula
the diagnostic specificity is 0.875, whereas for the CKD-
EPI-formula it is 0.891. The diagnostic sensitivity for the
MDRD-formula is 0.902, whereas for the CKD-EPI-
formula it is 0.878.
Discussion
The purpose of the present study is to compare the
application of compartment analysis techniques using
kinetic data of the GFR marker sinistrin with formula-
derived GFR estimates based on creatinine levels. The
kinetic procedure used here as a standard for com-
parison, has been validated previously by successfully
predicting in individual patients the concentration-
profile of a constant infusion experiment using results
obtained by a bolus experiment beforehand [18]. The
model-derived mGFR values were used to assess the reli-
ability of eGFR estimates obtained by the MDRD4- and
CKD-EPI-formulae in individuals with poor renal func-
tion as well as in subjects with normal or only mildly
disturbed kidney function. (Of all existing MDRD for-
mulae, we chose the MDRD4 equation as is was the
most common one at the time when this study was
started. Therefore, we used the earlier factor 186 instead
of the later established value 175.) Similar problems have
been studied in the literature [24,25]. A weak point of
the present study is that a retrospective data base arising
from everyday clinical routine had to be used. However,
similar results as in Figure 3 were presented previously
using mGFR values gained by constant infusion of inulin
versus creatinine based eGFR values [26].
As Table 2 shows, in patients with mGFR values indi-
cating severely disturbed renal function and, thus, high
concentrations of serum creatinine, eGFR methods may
suffice despite many objections against them [27-30]:
while the linear correlation coefficient still is far from
perfect in this range of renal function, the slope of the
regression line is not significantly different from unity,
and, even more important, the bias according to the
Bland-Altman technique is comparatively low. The neces-
sity for methods more exact than the simple creatinine-
based estimations, however, arises in the ranges of only
moderately restricted or even normal renal function. Infact, this deficit of creatinine-based estimations is not
really a surprise taking into account the flatness of the re-
lationship between serum creatinine concentrations and
GFR values in the range of normal or only mildly dis-
turbed renal function [31,32]. Besides the inherent weak-
ness of eGFR values in the creatinine-blind ranges of low
creatinine levels associated with laboratory errors, physio-
logical aspects are also to be considered in judging renal
function. Especially individual variations in distribution
volumes are not taken into account by eGFR formulae.
One might ask whether it is necessary to perform a
full kinetic analysis of the time-dependent concentration
curves of a marker like sinistrin or whether a simple
analysis of the area under the concentration curve would
suffice. There are several arguments supporting the full
kinetic analysis: first, considering the relevant large vol-
umes of marker solutions and the individually different
states of the veins of the patients, the administration of
the marker during a reasonable time – 3 minutes instead
of a truly instantaneous bolus injection – is possible.
Moreover, it is practically impossible to employ a too ex-
tended experimental protocol. Both these practical limi-
tations are in favor of the full kinetic analysis of the
applied marker. Second, the availability of sufficient
computer power enables one to extract more informa-
tion out of concentration curves of exogenous markers.
This is of importance in critical cases as, e.g., in live kid-
ney donors. Third, by means of the full kinetic analysis it
is possible to approach much more complicated scenar-
ios: for example, the immediate response of the kidneys
to external dietetic or pharmacologic loads, which may
cause both changes in GFRs as well as shifts in the
extracellular fluids from central to peripheral compart-
ments, can be studied with the same method, yielding
information on the state of the renal vasculature. For
this purpose it is necessary to perform two consecutive
experiments with the external loads in between. In the
second experiment, this procedure requires the calcula-
tion of the remaining marker amounts in the two com-
partments, since now these remaining amounts are
needed as initial values for the model identification de-
scribing the second experiment. Moreover, the kinetic
techniques allow also the determination of the error
bounds of the characteristic system constants [33]. The
application of an exogenous marker such as sinistrin and
the appropriate model-identification of the kinetics in-
volved enables one to determine the individual mGFR
and measures of the distribution process such as the
extracellular volume in the individual subject [34]. For a
critical judgment of the measured values in individual
patients reliable error measures of all these various phar-
macokinetic parameters are indispensable; and they can
be gained only by a model-fitting procedure. So while in
the present paper we have concentrated only on the
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nevertheless strongly advocate a full kinetic analysis be-
cause of its far-reaching potential.
Sinistrin is a clinically and physiologically suitable
marker and the bolus method assessed by compartmen-
tal kinetic analysis is a both reliable and clinically prac-
ticable procedure for the measurement of GFR. This is
of utmost importance in subjects requiring higher than
routine accuracy and precision as, e.g., in situations of
live kidney donor evaluations [35]. As stated in the
Amsterdam consensus guidelines [36] kidneys from live
donors with a GFR < 80 ml/min are associated with rela-
tive risk of graft loss of 2.28 compared to those with
higher GFR prior to nephrectomy. In this context GFR
measurement applying sinistrin kinetics appears to be of
particular use for exact determination of GFR in subjects
with normal or mildly impaired renal function. In sub-
jects with normal or close to normal renal function
commonly used GFR equations based on serum creatin-
ine are unreliable and thus should be avoided for the
evaluation of live kidney donors.
Conclusion
For correct determination of GFR, particularly in sub-
jects with normal or slightly impaired renal function
(CKD 1-2), kinetic procedures using an exogenous
physiologically and clinically suitable marker such as
sinistrin allow individualized GFR measurements in con-
trast to population-derived estimations by means of for-
mulae employing endogenous markers. Additionally, a
model-based technique enables one to assess consecu-
tive clearance tests with a pharmacological or dietetic
load in between. Such tests can be used for obtaining in-
formation on the properties of the renal functional re-
serve and the renal micro-vasculature, e.g., on changes
in its permeability caused by renal injuries [37]. Dynamic
renal function testing of this sort is not possible by
means of endogenous markers [38].
Summarizing it can be stated that both the accuracy
and precision of mGFR values achievable by the kinetic
procedure using sinistrin as exogenous marker as well as
the possibility for evaluation of the renal functional re-
serve appear to be of decisive importance in cases of live
kidney donors. Finally although so far eGFR methods
using creatinine levels only have been considered as suf-
ficiently satisfactory, recent developments suggest com-
binations of creatinine and cystatin C in regression
formulae as necessary improvements in GFR estimations
[39]. However, any such progress still suffers from the
drawback of employing statistical formulae derived from
population data based on endogenous markers and not
from individual kinetic measurements based on exogen-
ous markers.Abbreviations
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